FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
- Trials
- DPT02, DESTINY-Lung01, DESTINY-CRC02
- Drug
- Enhertu (fam-trastuzumab deruxtecan-nxki) · Anti-HER2 antibody-drug conjugate
- Condition
- Other solid neoplasm